Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses by Vander Heiden, Matthew G. et al.
Inhibition of pyruvate kinase M2 by reactive oxygen species
contributes to cellular antioxidant responses
Dimitrios Anastasiou1,2, George Poulogiannis1,2, John M. Asara1,3, Matthew B. Boxer4,
Jian-kang Jiang4, Min Shen4, Gary Bellinger1,5, Atsuo T. Sasaki1,2, Jason W. Locasale1,2,
Douglas S. Auld4,§, Craig J. Thomas4, Matthew G. Vander Heiden5,6, and Lewis C.
Cantley1,2,*
1Beth Israel Deaconess Medical Center, Department of Medicine-Division of Signal Transduction,
Boston, MA 02115, USA
2Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA
3Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
4NIH Chemical Genomics Center, National Human Genome Research Institute, National
Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, USA
5Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology
Cambridge, MA 02139, USA
6Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Abstract
Control of intracellular reactive oxygen species (ROS) concentrations is critical for cancer cell
survival. We show that, in human lung cancer cells, acute increases in intracellular concentrations
of ROS caused inhibition of the glycolytic enzyme pyruvate kinase M2 (PKM2) through oxidation
of Cys358. This inhibition of PKM2 is required to divert glucose flux into the pentose phosphate
pathway and thereby generate sufficient reducing potential for detoxification of ROS. Lung cancer
cells in which endogenous PKM2 was replaced with the Cys358 to Ser358 oxidation-resistant
mutant exhibited increased sensitivity to oxidative stress and impaired tumor formation in a
xenograft model. Besides promoting metabolic changes required for proliferation, the regulatory
properties of PKM2 may confer an additional advantage to cancer cells by allowing them to
withstand oxidative stress.
Control of the intracellular concentrations of reactive oxygen species (ROS) is critical for
cell proliferation and survival. In cells treated with growth factors, transient increases in
ROS concentrations are implicated in enhanced cell proliferation through inhibition of
phosphotyrosine phosphatases and PTEN, allowing amplification of tyrosine kinase and
phosphatidylinositol-3 kinase (PI-3K) signaling pathways (1). However, high concentrations
of ROS can also damage cellular components and compromise cell viability (2). Tumor
suppressor and oncogenic pathways frequently mutated in cancer commonly result in
increased accumulation of ROS (3–7). Furthermore, conditions associated with
tumorigenesis such as hypoxia, matrix detachment, mitochondrial dysfunction and
inflammation can all lead to excess production of ROS (8–12). Therefore, cancer cells are
particularly challenged in dealing with oxidative stress (2, 13).
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Detoxification of ROS and the repair of oxidatively damaged proteins depend primarily on
the availability of reduced glutathione (GSH). Glucose metabolism through the pentose
phosphate pathway provides NADPH to maintain glutathione in the reduced state (14, 15).
Glucose is also a major carbon source for biosynthetic processes (16). How glucose is
metabolized in cancer cells is determined, in part, by expression of the glycolytic enzyme
pyruvate kinase M2 (PKM2) (17). In contrast to its splice variant PKM1, which is expressed
in many adult tissues, PKM2 is allosterically activated in a feed-forward regulatory loop by
an upstream glycolytic metabolite, fructose-1,6-bisphosphate (FBP) and is susceptible to
inhibition by growth factor signaling through interaction with phosphotyrosine-containing
proteins (18). These properties of PKM2 allow proliferating cells to divert glucose into
anabolic pathways emanating from glycolysis in order to meet the increased biosynthetic
demands of proliferation.
Pyruvate kinase (PK) orthologues in many organisms, from bacteria to humans, are inhibited
by oxidants (19–22). Exposure of A549 human lung cancer cells to 1 mM H2O2, 250 μM
diamide (a thiol-oxidizing compound), or hypoxia (1% O2) [which causes increased ROS
production by mitochondrial complex III (23)], resulted in similar increases in intracellular
concentrations of ROS (fig. S1) and caused decreases in PKM2 activity (Fig. 1A and B)
(24). In all cases, incubation of cell lysates with dithiothreitol (DTT), a strong reducing
agent, restored PKM2 activity to nearly that of untreated cells, indicating that the effects of
treating cells with diamide, H2O2 or hypoxia on PKM2 activity reflect an oxidative event
that is reversible with a thiol reducing agent.
Association of PKM2 subunits into homotetramers is required for optimal enzymatic activity
(25). Diamide treatment impaired co-immunoprecipitation of endogenous PKM2 with Flag-
tagged PKM2 and this was reversed by adding DTT to the cell lysates prior to
immunoprecipitation (Fig. 1C). These results indicate either that oxidative stress induces
PKM2 subunits to dissociate in vivo or that it makes subunit association less stable during
cell lysis and immunoprecipitation. In either event, this change in association of PKM2
subunits after diamide treatment correlated with decreased enzymatic activity.
We examined whether diamide treatment differentially affected PKM2 versus PKM1
activity by assaying pyruvate kinase activity in lysates from cells engineered to express
equivalent amounts of either Flag-PKM1 or Flag-PKM2 with concomitant depletion of
endogenous PKM2 by shRNA (henceforth referred to as Flag-PKM1/kd cells or Flag-
PKM2/kd cells, respectively; kd: knock-down). Unlike that of PKM2, the activity of PKM1
did not change following diamide treatment (Fig. 1D). Consistent with this observation,
formation of complexes between Flag-PKM1 and endogenous PKM2 (using cells still
expressing endogenous PKM2) was unaffected by diamide (Fig. 1E). This result suggests
that the hetero-multimer of PKM1 and PKM2 is protected from oxidation-dependent
destabilization.
To assess a possible covalent modification of PKM2, we treated A549 cells with or without
diamide and subjected cell lysates to SDS-polyacrylamide gel electrophoresis (PAGE) under
non-reducing conditions. Subsequent protein immuno-blot analysis revealed that some
PKM2 from diamide-treated cells migrated faster (Fig. 2A, upper panel). This faster-
migrating form was not observed when SDS-PAGE was done under reducing conditions
(Fig. 2A, lower panel). Cysteine residues are particularly prone to oxidation because the
sulfhydryl group reacts with various oxygen species, and this reactivity can be influenced by
the local protein microenvironment (26). Structural analysis of PKM2 revealed three
cysteine residues that could affect subunit interaction, enzymatic activity, or both. Cys31 and
Cys424 are located at the subunit interaction interface whereas Cys358 is located in a beta
barrel that includes residues essential for catalytic activity (fig. S2A–B) (27). Substitution of
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Cys358 with Ser358 (C358S) abrogated the faster-migrating PKM2 band (Fig. 2B, upper
panels), but mutation of Cys31 or Cys424 did not (fig. S2C).
Lysis of cells under denaturing conditions in the presence of maleimide to block reduced
cysteines in proteins, followed by reduction of oxidized cysteines and labeling with biotin-
maleimide allows the detection of oxidized proteins with streptavidin (24). Using this
method, we detected biotin-labeled Flag-PKM2 in lysates of diamide-treated cells but not in
those of control cells (Fig. 2B, lower panels). In contrast, we did not detect biotinylated
Flag-PKM2(C358S). Furthermore, unlike Flag-PKM2, Flag-PKM2(C358S) still associated
with endogenous PKM2 after diamide treatment (Fig. 2C) and the enzymatic activity of the
C358S mutant was less sensitive to oxidant-induced inhibition (Fig. 2D). These results
indicate that although oxidation of other Cys residues in PKM2 may have minor effects on
PKM2 catalytic activity, oxidation of Cys358 primarily accounts for ROS-induced
inactivation.
Small molecule activators selectively increase the activity of PKM2 with no effects on
PKM1 (28). Treatment of purified recombinant PKM2 with the small molecule PKM2
activator DASA-10 (NCGC00181061, a substituted N,N′-diarylsulfonamide, fig. S3A)
prevented inhibition of PKM2 by H2O2 (fig. S3B). Incubation of A549 cells with 20 μM
DASA-10 caused a 2.8-fold increase in enzyme activity in the absence of diamide, and
prevented the diamide-induced inhibition of PKM2 activity (fig. S3C and Fig. 2E).
Furthermore, DASA-10 preserved the co-precipitation of endogenous PKM2 with Flag-
PKM2 after treatment of cells with diamide (Fig. 2F). Addition of DASA-10 after lysis of
diamide-treated cells was less effective in restoring PKM2 activity (fig. S3D). The activator
likely maintains PKM2 in an active conformation and thus prevents oxidation of Cys358;
however, PKM2 oxidation before addition of activator impairs the ability of the activator to
increase the enzymatic activity of PKM2. Likewise, despite the presence of Cys358 in
PKM1, the failure of this isoform to be inhibited by diamide (Fig. 1D), could be explained
by residues in PKM1 that stabilize the active tetramer and thereby block access of ROS to
Cys358.
To gain insights into the functional consequences of PKM2 inhibition under oxidative stress,
we investigated changes in cellular metabolism following diamide treatment in the presence
or absence of DASA-10 (fig. S4). We monitored flux of glucose into the pentose phosphate
pathway (PPP), which produces NADPH for ROS detoxification (14, 15, 29). Diamide
treatment stimulated PPP-dependent 14CO2 production from [1-14C]-glucose (p=0.02) in
A549 cells (Fig. 3A) indicating that flux into the oxidative branch of the PPP was enhanced
in response to oxidative stress (15, 29). In the presence of DASA-10, diamide did not cause
a significant increase in PPP-specific 14CO2 production (Fig. 3A), suggesting that ROS-
dependent inhibition of PKM2 is needed to maintain the availability of glucose-6-phosphate
(G-6-P) for flux into the PPP. Consistent with this idea, after 30 minutes of diamide
treatment, the cellular concentration of G-6-P increased 2.3-fold (Fig. 3B). Although this
could be a consequence of inhibiting any step in glycolysis or from stimulation of glucose
uptake and phosphorylation, the concentration of G-6-P decreased 75.5±17.6% when PKM2
inhibition by diamide was prevented by the presence of DASA-10 (Fig. 3B), indicating that
ROS-induced inhibition of PKM2 may account for the accumulation of G-6-P in response to
oxidative stress.
Glucose catabolism via the PPP provides NADPH required for glutathione reductase to
generate GSH for ROS detoxification. Cells expressing Flag-PKM2(C358S) in the absence
of endogenous PKM2 [henceforth referred to as Flag-PKM2(C358S)/kd cells] had lower
amounts of GSH than Flag-PKM2/kd cells (Fig. 3C, left). Similarly, treatment of parental
cells with either DASA-10 (Fig. 3C, right) or another structurally related PKM2 activator,
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DASA-58 (NCGC00185916, ML203, fig. S3A & S5A) resulted in lower amounts of GSH.
This decrease in GSH concentration was not observed in Flag-PKM1/kd cells even after
longer periods of activator treatment (fig. S5B). Because PKM1 activity is unaffected by
DASA-10 or DASA-58 (28), these results indicate that the effects of these compounds on
GSH concentration are a consequence of PKM2 activation, rather than off-target effects.
To test whether decreased abundance of GSH induced by the PKM2 activators impaired
cellular capacity for ROS detoxification, we measured intracellular ROS concentrations after
treatment of cells with H2O2. H2O2 elicited greater accumulation of ROS in PKM2
activator-treated cells than in DMSO-treated cells, and this difference was more pronounced
with increased amounts of H2O2 (Fig. 3D and fig. S5C). Genetic replacement of PKM2 with
PKM1 in mouse embryo fibroblasts (MEFs) (fig. S6 A & B) resulted in increased
accumulation of ROS in H2O2-treated cells compared to that in MEFs with intact PKM2
(fig. S6C). Thus, PKM2 inhibition due to oxidative stress contributes to a metabolic
response that can deplete ROS.
To test whether this mechanism is relevant for cell survival under oxidative stress, we
examined the effects of DASA-10 on diamide- or H2O2-induced cell death. In response to
treatment with either H2O2 or diamide, cell death was increased in PKM2 activator-treated
cells compared to DMSO-treated cells (Fig. 4A & fig. S7). Also, Flag-PKM2(C358S)/kd
cells were more sensitive to diamide than Flag-PKM2/kd cells (Fig. 4B).
We monitored cell mass accumulation of Flag-PKM2/kd or Flag-PKM2(C358S)/kd cells
over several days in an atmosphere of 21% or 1% oxygen to determine whether PKM2
inhibition under conditions of increased endogenous ROS levels induced by hypoxia (fig.
S1) was functionally relevant. With standard tissue culture concentrations of glucose (25
mM), the proliferation of the two cell-lines was indistinguishable at either 21% oxygen (fig.
S8 A&B) or 1% oxygen (fig. S8C). In contrast, when the glucose concentration in the media
was reduced to a physiological level of 5.6 mM, Flag-PKM2(C358S)/kd cells showed a
modest but reproducible (p=0.0041) decrease in cell mass accumulation (fig. S8D). This was
more evident when cells were grown in 1% oxygen (Fig. 4C). Under the same culture
conditions, we could detect oxidation of endogenous PKM2 which was diminished when
cells were treated with the anti-oxidant N-acetyl-cysteine (NAC) (fig. S9A). In contrast, we
detected neither biotin-maleimide labeling (fig. S9B), nor a significant change in the
enzymatic activity of Flag-PKM2(C358S) under hypoxia (fig. S9C). These data indicate that
the C358S mutant is refractory to hypoxia-induced oxidation. When the cell-permeable GSH
analogue glutathione-monoethylester (GSH-MEE) was present in the medium for the
duration of the experiment, there was no difference in cell mass accumulation between Flag-
PKM2(C358S)/kd cells and Flag-PKM2(WT)/kd cells (Fig. 4D). Furthermore, a
phosphotyrosine-containing peptide with amino acid sequence corresponding to the optimal
PKM2 binding motif (18) inhibited the activities of both Flag-PKM2 and Flag-
PKM2(C358S) to a similar degree (fig. S9D) suggesting that the impaired proliferation of
Flag-PKM2(C358S)/kd cells is unlikely to be a result of differential sensitivity to growth
factor inhibition of the C358S mutant relative to that of PKM2(WT). Therefore, the
diminished proliferation of Flag-PKM2(C358S)/kd cells appears to result from impaired
antioxidant capacity. Inhibition of PKM2 after oxidative stress contributes to sustaining cell
survival when endogenous ROS accumulate.
To determine whether the proposed role for PKM2 in survival under oxidative stress is
relevant in vivo, we injected cells into immunocompromised (nu/nu) mice and assayed
formation of tumors (fig. S10A). Half the mice were given access to standard water and half
to water containing NAC throughout the experiment. Tumors derived from Flag-
PKM2(C358S)/kd cells were significantly (p=0.011) smaller compared to those expressing
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wild-type Flag-PKM2 (Fig. 4E and fig. S10). This difference in tumor growth was alleviated
in mice treated with NAC. Thus, regulation of PKM2 via oxidation of Cys358 is critical
under these conditions for optimal tumor growth.
Cancer cells experience a substantial need for providing reducing power in the form of
NADPH to fuel biosynthesis of lipids and nucleotides that are in high demand during
proliferation (16). Consequently, under conditions of oxidative stress, NADPH supply must
be appropriately enhanced in order to sustain proliferation while maintaining ROS
homeostasis through GSH. Our data indicate that, besides metabolic reprogramming
functions associated with promoting anabolic processes, expression of a specific pyruvate
kinase isoform, PKM2, confers additional advantages to cancer cells by allowing them to
sustain anti-oxidant responses and thereby support cell survival under acute oxidative stress.
As increasing PKM2 activity would compromise both its pro-anabolic and anti-oxidant
functions, the use of small molecule PKM2 activators may be an appropriate approach to
interfere with cancer cell metabolism for therapeutic purposes.
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Figure 1. ROS-promoted dissociation of PKM2 subunits and inhibition of enzymatic activity
(A) A549 human lung cancer cells were treated with 250 μM diamide or 1mM H2O2 for 15
min. After cell lysis pyruvate kinase activity was assayed in the presence or absence of DTT.
% PKM2 activity (mean ± SD) relative to untreated cells for each condition is shown (:
p<0.001, §: p<0.01, #: p<0.05, 2-way ANOVA with Bonferroni post-tests, N=3).
(B) A549 cells were cultured in medium containing 5.6 mM glucose for 3 hours under 21%
O2 or 1% O2. After cell lysis, PKM2 activity was assayed as in (A) (Student’s t-test, N=3).
(C) A549 cells were engineered to express Flag-PKM2 (arrows). Cells were left untreated or
were diamide-treated as in (A) and equal portions of lysates prepared under non-reducing
conditions were supplemented or not with DTT (1 mM final concentration). Lysates were
then subjected to immunoprecipitation with anti-Flag agarose beads in the presence or
absence of DTT, followed by SDS-PAGE and western blot.
(D) A549 cells expressing Flag-PKM1 or Flag-PKM2 in the absence of endogenous PKM2
(referred to in the text as Flag-PKM1/kd or Flag-PKM2/kd) were generated as in (17).
Expression of Flag-tagged proteins and depletion of endogenous PKM2 were confirmed by
western blot with an antibody recognizing both PKM1 and PKM2 (right panel). Left panel:
lysates of diamide-treated (250 μM, 15 min.) cells were prepared and assayed for pyruvate
kinase activity as in (A). % pyruvate kinase activity (mean ± SD) for each condition relative
to untreated Flag-PKM2/kd cells is shown. Numbers denote % difference in PK activity ±
SD between diamide-treated versus non-treated Flag-PKM1/kd or Flag-PKM2/kd cells,
respectively.
(E) A549 cells expressing Flag-PKM1 or Flag-PKM2 were treated with diamide (250 μM,
15 min.) and, after cell lysis, immunoprecipitation to assess the amount of endogenous
PKM2 associated with the tagged PKM isoforms was performed as in (C).
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Figure 2. Protection of PKM2 from ROS-induced inhibition by substitution of Cys358 with
Ser358 or by small molecule PKM2 activators
(A) A549 cells were treated with 1mM diamide for 15 min., lysed and analyzed by SDS-
PAGE under reducing (lower panel) or non-reducing (upper panel) conditions. Asterisks
throughout the figure mark bands corresponding to reduced PKM2 (*) or oxidized (**)
PKM2.
(B) Upper panel: A549 cells expressing Flag-PKM2 or Flag-PKM2(C358S) were treated
with 250 μM diamide for 15 minutes, lysed, and analyzed by SDS-PAGE under reducing or
non-reducing conditions. Lower panel: A549 Flag-PKM2/kd or Flag-PKM2(C358S)/kd cells
were treated with diamide as above. Oxidized proteins were labeled with biotin-maleimide
(24), purified with streptavidin-sepharose beads and probed for the presence of Flag-PKM2
or Flag-PKM2(C358S) with Flag antibody.
(C) A549 cells expressing Flag-PKM2 or Flag-PKM2(C358S), were treated with 250 μM
diamide for 15 min., lysed without DTT and split into equal portions that were
supplemented with or without DTT (1 mM final concentration). After immunoprecipitation
with anti-Flag agarose, immunoprecipitates were analyzed by reducing SDS-PAGE and
western blot with the indicated antibodies.
(D) A549 Flag-PKM2/kd or Flag-PKM2(C358S)/kd cells were treated with diamide as in
(C) and pyruvate kinase activity was assayed in cell lysates in the presence or absence of 1
mM DTT. % PKM2 activity (mean ± SD) relative to untreated cells for each condition is
shown.
(E) Medium containing 20 μM PKM2 activator DASA-10 (28) was added to A549 cells at
t=−1h; diamide was then added directly to the media at a final concentration of 250 μM at t=
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−15 min. Cells were harvested at t=0, lysed, and pyruvate kinase activity in lysates was
assayed in the presence or absence of 1 mM DTT. PKM2 activity is shown as in (D).
(F) A549 cells expressing Flag-PKM2 were treated with DASA-10 and diamide as in (E)
and the respective lysates were subjected to immunoprecipitation with anti-Flag agarose
under non-reducing conditions. Immunoprecipitates were analyzed by reducing SDS-PAGE
followed by western blot with a PKM2 antibody.
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Figure 3. Changes in glucose metabolism required for cellular antioxidant responses are
supported by ROS-induced inhibition of PKM2
(A) PPP-dependent glucose oxidation to CO2. A549 cells were seeded and, after 24 hours,
media were supplemented with [1-14C]-glucose or [6-14C]-glucose plus 10 μM DASA-10
and 100 μM diamide where indicated. Released 14CO2 was measured after a 3-hour
incubation of cells with labeled glucose. The rate of 14CO2 production from glucose via the
PPP was calculated as described (24). Mean PPP-dependent 14CO2 release rates relative to
(DMSO, - Diamide) ± SD are shown (Student’s t-test, N=3).
(B) A549 cells were treated with 10 μM PKM2 activator DASA-10 or DMSO for 1 hour
prior to addition of 250 μM diamide directly into the medium. Cellular metabolites were
harvested at t=30 min. and analyzed by liquid chromatography coupled to triple quadrupole
tandem mass spectrometry (LC-MS/MS) (24). Bars represent mean concentrations of
glucose-6-phosphate at t=30 min. relative to t=0 min. ± SD (N=3). Statistical analysis details
are described in (24).
(C) Intracellular GSH concentrations of A549 Flag-PKM2/kd and Flag-PKM2(C358S)/kd
cells (left panel) or A549 cells treated either with PKM2 activator DASA-10 (10 μM) or
DMSO for 1 hour (right panel) were assessed using ThiolTracker™ Violet. Mean GSH
concentrations relative to WT or DMSO-treated cells, respectively, are shown (Student’s t-
test, N=3).
(D) After treatment with DMSO or 10 μM PKM2 activator DASA-10 for 1 h, A549 cells
were incubated with the ROS-sensitive fluorescent dye CM-H2DCFDA and H2O2 was
added at the indicated concentrations. Cells were then collected after 15 minutes and ROS-
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dependent fluorescence was measured by flow cytometry. Mean fluorescence intensities ±
SD are shown and p values were calculated by 2-way ANOVA with Bonferroni post-tests
(N=3).
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Figure 4. Promotion of cancer cell survival and tumor growth under oxidative stress by PKM2
inhibition
(A) DASA-10 (10 μM) or DMSO was added to H1299 human lung cancer cells at t=−1h. At
t=0, 150 μM diamide was added directly into the medium. At t=+3h, cells were collected by
trypsinization and stained with propidium iodide (PI). Dead (PI-stained) cells were scored
by flow cytometry (Student’s t-test, N=3).
(B) H1299 Flag-PKM2/kd or H1299 Flag-PKM2(C358S)/kd cells were treated with 150 μM
diamide for 3 hours, at which point dead cells were detected as in (A) (Student’s t-test,
N=3).
(C and D) H1299 Flag-PKM2/kd or H1299 Flag-PKM2(C358S)/kd cells were seeded in
medium containing 5.6 mM glucose and cultured in 1% oxygen (O2) in the absence (C) or
presence (D) of 4 mM glutathione monoethyl ester (GSH-MEE). Cells were fixed at the
indicated time points and cell mass was quantified by crystal violet staining (C: p<0.0001, 2-
way ANOVA, N=3) (24).
(E) Equal numbers of H1299 Flag-PKM2/kd or Flag-PKM2(C358)/kd cells were injected
into the left and right flanks, respectively, of immunocompromised mice. Half had access to
normal water and the other half to water supplemented with 40 mM NAC throughout the
experiment. Upper panel: photographs of dissected tumors in pairs. The bar graphs represent
tumor weight ratios with corresponding value above each bar (left) and mean weight ratios ±
SD (right) (p value calculated by Student’s t-test).
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